Grants Search Results

Since the majority of children with acute lymphoblastic leukemia (ALL) will survive, understanding how to limit the acute and long-term toxicities of treatment is increasingly important. Toxicities of the bone, including fracture and osteonecrosis, are serious complications. Dr. Vrooman's project accesses how bone mineral density changes in children being treated for ALL, so future interventions may decrease skeletal morbidity in these children. She is funded by P.A.L.S. Bermuda with funds raised through the St. Baldrick's Foundation.

While current therapies have greatly improved the overall survival of children with leukemia, patients with acute myeloid leukemia (AML) still have a poor outcome. This research focuses on determining the role played by the CALM gene in the onset of leukemias. These studies improve our understanding of how CALM-rearranged leukemias develop and contribute to the development of novel therapeutic strategies to fight childhood leukemias.

Generously sponsored by Markit. Treatment for acute lymphoblastic leukemia can be particularly devastating to a child's developing brain, leading to deficient short-term memory and attention or more serious events like seizures or strokes. This research focuses on how the cough medicine dextromethorphan may help reverse severe, stroke-like neurotoxicity among children treated with chemotherapy drug methotrexate and could possibly also prevent such side effects before they occur. The most promising drugs will be rapidly advanced into clinical trials for children with leukemia, designed to decrease the neurotoxic effects of chemotherapy.

Cancer affects every part of patients and their families' lives. Self-image, thinking clearly, anxiety, depression, social isolation and fear of recurrence are all problems that teens and young adults with cancer face, while resuming normal development and being monitored for many problems caused by cancer and its treatment. This research is to create developmentally sensitive information and make it available through touch-screen technology, connecting teens and young adults with their health care team and community resources in real-time. This helps identify, communicate and maximize the benefits of clinical care while helping them reintegrate into school and work.

Fatigue is a pervasive, distressing symptom for children and teens with cancer. Decreasing fatigue and improving physical activity are important to provide energy for the normal activities of childhood that are important to ongoing development. A small, cost-effective device called the FitBit measures motion and provides daily feedback to the wearer. Children ages 6 to 18 in maintenance treatment for acute lymphoblastic leukemia use the FitBit, and researchers determine if it is accurate, if it helps childhood cancer patients to be more active, and if more active patients have less fatigue when getting steroids during treatment.

Little is known about the long-term impact of communication about prognosis on children with cancer and their families. The goal of this project is to increase parents' ability to make value-driven decisions for care of their children with cancer and to adjust to this life-changing event in the best way possible. A longitudinal observational study evaluates long-term outcomes, using questionnaire-based parent interviews to assess parental decision- making and psychological and medical outcomes of disclosure. The cohort involves 194 children diagnosed between April 2003 and May 2005, so long-term assessment of their outcomes is now possible. Dr. Mack is funded by P.A.L.S. Bermuda with funds raised through the St. Baldrick's Foundation.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer, perhaps encouraging the future choice of childhood cancer research as a specialty.

This grant helps fund a Presidential Symposium focused on medical education, an essential subject matter for physicians.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer, perhaps encouraging the future choice of childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer, perhaps encouraging the future choice of childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer, perhaps encouraging the future choice of childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer, perhaps encouraging the future choice of childhood cancer research as a specialty.

Based on progress to date, Dr. Engel was awarded a new grant in 2013 to fund an additional two years of this Scholar award. Approximately one thousand children are diagnosed with acute myeloid leukemia (AML) each year in the United States, and only about 50% survive. Dr. Engel's research is to gain a better understanding of how normal blood cell development is altered in AML and how we can overcome these alterations to regain control over blood cell growth and development. Dr. Engel began his research at Vanderbilt University Medical Center and moved to the Huntsman Cancer Institute in 2010.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

Through this partnership with the Children's Cancer Foundation, proceeds from St. Baldrick's head-shaving events in Hong Kong support life-saving childhood cancer research in Hong Kong. The project supported by this grant is a multicenter clinical study testing the best treatment strategy for Chinese children with Acute Lymphoblastic Leukemia. It started from 2008 and completed at the end of 2012. All the hospitals treating children with cancer in Hong Kong participated in this study, and 12 other centers in mainland China also joined the study. They performed a special test on the patients to find any residual leukemia cells in the body after initial chemotherapy treatment in the first 3 months of treatment. The special tests included “flow cytometry for leukemia specific antigen’ and “Quantitative Polymerase Chain Reaction for leukemia DNA”.

Based on progress to date, Dr. Federman was awarded a new grant in 2012 to fund an additional two years of this Scholar award. We already have many powerful drugs to treat cancer but lack the means to deliver them directly to the intended targets (cancer cells), and as a result, cancer patients suffer significant side effects. Dr. Federman tests new ways of delivering anti-cancer treatments more directly using nanoparticles programmed to recognize particular cancer cells.